SynthesisFrontiers in pharmacology2025
Tianqi Jiangtang Capsule in the treatment of patients with diabetes: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tianqi Jiangtang Capsule (TJC) is a commercial Chinese polyherbal preparation (CCPP) commonly used as adjunctive therapy for glucose management in diabetes. While its potential multi-system effects have been observed, a systematic evaluation focusing on glycemic control remains limited. This study aims to primarily assess the glucose-lowering efficacy of TJC in diabetic patients. Materials and Methods: We conducted a comprehensive search for relevant randomized controlled trials (RCTs) across nine electronic databases from their inception to 1 September 2025. Two independent reviewers performed trial selection, data extraction, and risk-of-bias assessment. Meta-analyses of efficacy and safety outcomes were performed using RevMan 5.3 and Stata 17. Evidence quality was evaluated using GRADE methodology. Results: 13 RCTs involving 1,298 diabetic patients were included. Compared with conventional treatment (CT) alone or combined with placebo, TJC plus CT significantly improved primary glycemic parameters: glycated hemoglobin (mean difference [ Conclusion: TJC significantly improves glycemic control in patients with diabetes and shows potential multi-system benefits. However, its efficacy and safety profile require further validation in large-scale, high-quality trials, particularly regarding the influence of genetic factors on treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.